These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31356696)

  • 21. Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML.
    Mika T; Ladigan S; Schork K; Turewicz M; Eisenacher M; Schmiegel W; Schroers R; Baraniskin A
    Blood Cells Mol Dis; 2019 Jul; 77():103-108. PubMed ID: 31029023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
    Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Grönberg H; Rantalainen M
    J Natl Cancer Inst; 2018 Oct; 110(10):1094-1101. PubMed ID: 29506270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
    Pullarkat V; Aldoss I
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients.
    Han Y; Cui J; Lu Y; Sue S; Arpaia E; Mak TW; Minden MD
    Leuk Res; 2012 Nov; 36(11):1339-46. PubMed ID: 22902056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
    Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
    Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
    Kassem NM; Medhat N; Kassem HA; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
    Kim KI; Kim TK; Kim IW; Ahn KS; Yoon SS; Shin WG; Oh JM
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):317-24. PubMed ID: 22672209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
    Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
    Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
    Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
    Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Si T; Lu Y; Li F; Jiang L; Pei R; Zhou JX
    Leuk Lymphoma; 2018 Jan; 59(1):114-120. PubMed ID: 28836868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
    Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
    Su YZ; Wang CB; Zhou Y; Sun NT
    Genet Mol Res; 2015 May; 14(2):5181-7. PubMed ID: 26125711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
    Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
    Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
    Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
    Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.